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Case report
The patient, a 37-year-old male with a history of  peptic 
ulcer disease, presented to the emergency department after 
syncope. At the time of  presentation, the patient’s hemo-
globin was 6.8 g/dl, and stool guaiac was positive. Al-
though the patient was not grossly bleeding per rectum, 
given the patient’s history of  peptic ulcer disease, the pa-
tient underwent an esophagogastroduodenoscopy (EGD) in 
the emergency department to evaluate for upper gastroin-
testinal bleeding. EGD revealed no gross lesions in the 
esophagus; however, enlarged gastric folds, duodenal ero-
sion, and two umbilicated nodules were found in the duo-
denum with no evidence of  active bleeding. After receiving 
four units of  packed red blood cells and not responding 
appropriately, the patient underwent a nuclear medicine 
gastrointestinal bleeding scan for evaluation of  a bleeding 
source. Images show bleeding in the distribution of  the 
small bowel (Fig. 1).
Given the results of  the bleeding scan, the patient un-
derwent a repeat EGD that showed umbilicated nodules in 
the duodenum with blood at the second, third, and fourth 
portions of  the duodenum. The patient was then taken for 
laparotomy for bleeding duodenal ulcers and underwent 
duodenectomy of  the first and second portions of  the duo-
denum. The pathology report from the duodenal nodules 
revealed small-bowel mucosa showing focal gastric foveolar 
metaplasia, marked Brunner gland hyperplasia, and focal 
small nests of  neuroendocrine cells staining positive for 
chromogranin, synaptophysin, and gastrin. These findings 
were suspicious for an underlying carcinoid or gastrinoma. 
CT scan of  the abdomen and pelvis on the same day as the 
laparotomy revealed small-to-borderline enlarged mesen-
teric lymph nodes measuring up to 1.3 x 1.0 cm. Biopsy of  
a peripancreatic lymph node revealed metastatic, well-
differentiated gastrinoma. 
In addition to the gastrointestinal bleeding, which was 
thought to be due to a gastrin-secreting tumor, the patient 
had an elevated calcium level (11.5 mg/dl) on routine lab 
tests. Parathyroid hormone level was investigated at this 
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Multiple endocrine neoplasia 1 (MEN 1) is a rare genetic disorder classically characterized by a predis-
position to tumors of  the parathyroid glands, anterior pituitary gland, and pancreatic islet cells (1). In 
addition to exhibiting these characteristic tumors, MEN 1 patients also have an increased propensity for 
other tumors such as carcinoids, adrenal adenomas, angiofibromas, and lipomas (1-3). Although MEN 1 
is rare, with a prevalence of  approximately 2 per 100,000 people, recognition of  this syndrome is ex-
tremely important for both patient treatment and evaluation of  family members (1, 4). The tumors of  
MEN 1 are usually benign; however, malignancy of  some carcinoid, islet cell, and gastrointestinal tract 
tumors can cause mortality (5-8). Diagnosis of  MEN 1 is usually made by a combination of  history and 
physical examination, biochemical serum testing, and various imaging modalities (9, 10). We present a 
classic case of  MEN 1 with unique presentation and diagnosis using predominantly nuclear imaging in 
order to emphasize the role of  nuclear imaging in diagnosing and treating MEN 1.
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point and found to be markedly elevated, at 470 pg/ml. 
The patient subsequently underwent ultrasound of  the thy-
roid that showed two discrete nodules posterior to the left 
thyroid lobe. One nodule was posterior to the upper pole of 
the left lobe and measured approximately 1.4 x 1.9 x 1.7 
cm. The second, well-defined hypoechoic nodule was lo-
cated posterior to the mid and lower pole of  the left lobe 
and measured 2.0 x 1.5 x 1.9 cm. These findings were sug-
gestive of  multiple parathyroid adenomas. The patient next 
underwent a nuclear medicine parathyroid scan. Delayed 
images showed a large persistent focus of  increased radio-
tracer uptake in the mid-left thyroid lobe, and a smaller 
persistent focus of  increased radiotracer uptake in the lower 
pole of  the right thyroid lobe. Two questionable foci of  less 
intense persistent tracer uptake were also noted in the up-
per pole of  the right thyroid lobe and the lower pole of  the 
left thyroid lobe. Findings were consistent with multiple 
parathyroid adenomas or parathyroid hyperplasia (Fig. 2). 
Given the findings of  gastrinoma and parathyroid pa-
thology, a diagnosis of  MEN 1 was suspected. A prolactin 
level was drawn and returned elevated, at 46.4 ng/ml. Sub-
sequently, MRI of  the head with contrast revealed an area 
of  diminished enhancement in the pituitary gland to the 
right of  midline, measuring 4 mm, with no mass effect on 
adjacent structures, suggestive of  a pituitary microade-
noma. The patient also underwent an octreotide scan; re-
sults were consistent with metastatic somatostatin-receptor-
positive malignancy involving the lymph nodes in the porta 
hepatis region (Fig. 3). 
 
Discussion
The clinical presentation of  MEN 1 depends on the en-
docrine organs involved, as well as the level of  the hor-
mones secreted (1). Therefore, the presentation varies be-
tween patients and may reflect elevated levels of  one or 
multiple hormones. Although the initial clinical manifesta-
tion of  MEN 1 is usually hyperparathyroidism, some pa-
tients may present with symptoms of  Zollinger-Ellison syn-
drome prior to symptoms of  primary hyperparathyroidism 
(8, 9, 11, 12). The symptoms of  hyperparathyroidism in-
clude musculoskeletal complaints, generalized weakness, 
altered mental status, and in rare cases nephrolithiasis, 
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Fig. 1. 37-year-old male with MEN 1. The patient was injected with 24.8 mCi Tc-99m-labeled red blood cells, and images of the 
abdomen were acquired in the anterior projection for 90 minutes. Images show bleeding in the distribution of the small bowel 
during 61 to 75 minutes of imaging. 
whereas the symptoms from a gastrin-secreting tumor con-
sist of  abdominal pain, diarrhea, or complications of  peptic 
ulcer disease, such as ulcer perforation or bleeding (1). In 
this case, the patient with a history of  peptic ulcer disease 
presented with syncope, anemia, and gastrointestinal bleed-
ing, which are consistent with Zollinger-Ellison syndrome. 
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Fig. 2A & B. 37-year-old male with MEN 1. The patient was injected with 25.8 mCi Tc-99m sestamib,i and images of the neck 
and chest in the anterior view were acquired at 10 minutes and at 2 hours. Early images (2A) show tracer uptake in both lobes 
of the thyroid gland, more prominent in the left mid thyroid and lower pole of right thyroid. Delayed images (2B) demonstrate a 
large persistent focus of increased radiotracer uptake in the mid left thyroid lobe and a smaller persistent focus of increased 
radiotracer uptake in the lower pole of the right thyroid lobe. Two questionable foci of less intense persistent tracer uptake also 
appear in the upper pole of the right thyroid lobe and the lower pole of the left thyroid lobe. Findings are consistent with multi-
ple parathyroid adenomas or parathyroid hyperplasia.
Although this patient exhibited symptoms only from 
Zollinger-Ellison syndrome, patients may also present with 
symptoms of  pituitary tumors, including headache and 
visual-field defects. Prolactinomas, which are the most 
common pituitary tumor in MEN 1, can present differently 
in male and female patients. Male patients may exhibit 
erectile dysfunction or decreased libido, while female pa-
tients may develop amenorrhea and galactorrhea. Other 
pituitary tumors such as growth-hormone-secreting tumors 
may result in acromegaly, while cortisol-secreting tumors 
The role of nuclear imaging in multiple endocrine neoplasia 1 (MEN 1)
RCR Radiology Case Reports | radiology.casereports.net 4 2010 | Volume 5 | Issue 4
Fig. 3A-D. 37-year-old male with MEN 1. The patient 
was injected with 6.4 mCi In-111 octreotide, and images 
were acquired in the anterior and posterior projections 
at 4 hours (3A) and 24 hours (3B). SPECT images were 
also obtained at 24 hours (3C, axial, and 3D, coronal). 
Findings are consistent with metastatic somatostatin-
receptor-positive malignancy involving the lymph nodes 
either in the peripancreatic or porta hepatis region. In 
addition, diffusely increased radiotracer uptake in the 
neck likely corresponds to the parathyroid pathology 
seen on the prior parathyroid scan. 
may present as Cushing syndrome. In addition, nonsecret-
ing pituitary tumors may also occur (1, 10, 13, 14). 
Due to the many possible combinations of  tumors and 
hormone levels in MEN 1, patients may present with a 
myriad of  symptoms as described above, most of  which are 
nonspecific. Therefore, diagnosis of  MEN 1 is difficult and 
should include extensive history, physical examination, bio-
chemical serum testing, and (depending on these results) 
focused imaging studies. Because the workup of  MEN 1 is 
specific to each individual case, there is no standard proto-
col or algorithm for diagnosing MEN 1, and therefore phy-
sicians do not always take full advantage of  the benefits of  
nuclear imaging. Although MRI, CT, and ultrasound may 
provide sufficient anatomical information, nuclear imaging 
can provide additional functional detail (10). Nuclear imag-
ing is frequently used for the diagnosis of  sporadic parathy-
roid adenomas, parathyroid hyperplasia, and neuroendo-
crine tumors; however, nuclear imaging is not always used 
in the diagnosis of  MEN 1 syndrome. 
Numerous radiotracers are available for endocrine tumor 
imaging, including Tc-99m sestamibi, In-111 pentetreotide, 
flurodeoxyglucose (F-18 FDG), I-131 meta-
iodobenzylguanidine (I-131 MIBG), and Ga-67 (15). Each 
of  these tracers has advantages and disadvantages. Tc-99m 
sestamibi, for example, concentrates in cells with high mi-
tochondrial content and is very useful in detecting parathy-
roid adenomas; it has a sensitivity of  approximately 90% or 
even higher with the addition of  SPECT imaging (15, 16). 
In-111 pentetreotide is extremely beneficial in detecting 
neuroendocrine tumors because it acts on somatostatin 
receptors, making it highly tumor-specific. In contrast, 
FDG accumulates in any region with increased glucose 
metabolism, such as areas of  inflammation, therefore mak-
ing it less tumor-specific (17). Another drawback of  using 
FDG for neuroendocrine imaging is that it classically causes  
false negatives for carcinoid tumors and tumors less than 1 
cm (18). However, one advantage of  FDG is its ability to 
detect dedifferentiated neuroendocrine tumors that no 
longer concentrate other tracers. One tracer that is ex-
tremely helpful for detecting adrenal tumors such as pheo-
chromocytoma and neuroblastoma is I-131 MIBG (15). 
Ga-67 is another tracer that is taken up by a variety of  tu-
mors; however, it does not seem to be as reliable as other 
tracers for consistently detecting neuroendocrine 
tumors (19). 
Some newer tracers that may be used for neuroendocrine 
tumor imaging include Gallium-68-labeled somatostatin 
analogues such as Ga-68-DOTA-NOC, which may be used 
in PET-CT. Ga-68-DOTA-NOC is an excellent tracer for 
imaging somatostatin-receptor-positive tumors, and pro-
vides a high target-to-nontarget ratio that allows for the 
detection of  very small lesions, especially of  lymph node 
and bone metastases (20). 18-F-DOPA PET has also proven 
useful for detection and staging of  neuroendocrine tumors 
(21). Other tracers being studied include gastrin-receptor 
analogs that may provide additional information when 
somatostatin-receptor-positive scintigraphy is negative (22). 
Because of  the efficacy of  therapy for hyperparathyroid-
ism and pituitary tumors, malignant pancreatic-islet-cell 
and gastrointestinal tumors are the primary life-threatening 
components of  MEN 1. Therefore, diagnosis and treatment 
of  these tumors should be the primary concern (5-8). The 
presence of  a high density of  somatostatin receptors in 
numerous neuroendocrine and some nonneuroendocrine 
tumors allows radiolabeled somatostatin analogs to be used 
to image a variety of  tumors and detect both primary and 
metastatic foci. Indium-111 pentetreotide is primarily use-
ful in evaluating carcinoids (sensitivity 85% to 95%) and 
gastrinomas; however, additional tumors such as 
pancreatic-islet-cell neoplasms, pituitary adenomas, pheo-
chromocytomas, neuroblastomas, paragangliomas, medul-
lary carcinoma of  the thyroid, small-cell lung cancer, and 
meningiomas may also be assessed with this 
radiopharmaceutical (15). 
Most of  the tumors listed in the previous paragraph are 
successfully imaged using radiolabeled somatostain analogs, 
with sensitivities ranging from 80% to 100% (15). Excep-
tions are insulinomas (50% to 60% sensitivity), and medul-
lary thyroid carcinoma (65% to 70% sensitivity) (15). 
Indium-111 pentetroeotide is not useful in pancreatic car-
cinomas of  exocrine origin, because they do not express 
somatostatin receptors (15). Another important point is that 
because somatostatin receptors are expressed in some non-
neoplastic, chronic inflammatory processes, such as granu-
lomatous lesions (sarcoidosis, tuberculosis), Crohn’s disease, 
ulcerative colitis, and rheumatoid arthritis, these entities 
may serve as possible sources of  false-positive results (15). 
One topic that we would like to emphasize is the benefit 
of  whole-body imaging in the workup of  MEN 1. Whole-
body gamma-camera imaging allows for cost-effective 
screening of  patients with suspected or known endocrine 
tumors. Once injected with radionuclide, the patient has 
already received the radiation dose, and therefore whole-
body scanning does not expose the patient to more radia-
tion than a limited scan. Information acquired from whole-
body imaging may confirm or reveal the presence of  a le-
sion, detect metastases from a primary tumor, or diagnose 
neuroendocrine conditions in which multiple lesions exist. 
In addition, because somatostatin-receptor expression is 
seen more frequently in well-differentiated tumors, visuali-
zation may suggest a more favorable prognosis. Patients 
with positive indium-111 pentetreotide images are often 
eligible for octreotide treatment because the documentation 
of  somatostatin receptors provides a higher likelihood of  
controlling hormonal hypersecretion (15). 
In addition to planar whole-body imaging, SPECT may 
increase the sensitivity of  the exam, especially in the upper 
abdomen where kidney, spleen, and often gallbladder activ-
ity may obscure imaging of  the pancreas and duodenum. 
SPECT may also be useful in better evaluating suspected 
liver metastases. Lastly, SPECT can aid in preoperative 
planning and provide the surgeon with additional informa-
tion about patients who are surgical candidates (15). 
SPECT-CT, which provides simultaneous functional and 
anatomic information, further increases sensitivity and 
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specificity and thus results in improved diagnosis and pa-
tient management (15). 
In conclusion, the diagnosis of  MEN 1 ideally involves 
intravenous injection of  a single tracer followed by whole-
body imaging in which all endocrine tumors would be visu-
alized. Because of  the various types of  endocrine tumors 
and different stages of  patient presentation, this is not cur-
rently possible. Imaging studies and tracers must be selected 
on a patient-to-patient basis with regard to the individual 
patient’s history, physical examination, and serum bio-
chemical results. Use of  the appropriate tracers and imag-
ing techniques including nuclear tests can benefit both pa-
tients and their families. 
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